Trial Profile
Xenon in the treatment of panic disorder: an open-label study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2017
Price :
$35
*
At a glance
- Drugs NBTX 001 (Primary) ; Oxygen (Primary)
- Indications Panic disorder
- Focus Therapeutic Use
- Sponsors Nobilis Therapeutics
- 14 Jun 2017 According to a Nobilis Therapeutics, Inc. media release, results from this study were published in Journal of Translational Medicine.
- 18 Apr 2017 New trial record